{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:35Z","timestamp":1794047435007,"version":"4.8.0"},"reference-count":41,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Subsets of multiple myeloma (MM) and monoclonal gammopathies of undetermined significance (MGUS) present with a monoclonal immunoglobulin specific for hepatitis C virus (HCV), thus are presumably HCV-driven, and antiviral treatment can lead to the disappearance of antigen stimulation and improved control of clonal plasma cells. Here we studied the role of hepatitis B virus (HBV) in the pathogenesis of MGUS and MM in 45 HBV-infected patients with monoclonal gammopathy. We analyzed the specificity of recognition of the monoclonal immunoglobulin of these patients and validated the efficacy of antiviral treatment (AVT). For 18 of 45 (40%) HBV-infected patients, the target of the monoclonal immunoglobulin was identified: the most frequent target was HBV (n=11), followed by other infectious pathogens (n=6) and glucosylsphingosine (n=1). Two patients whose monoclonal immunoglobulin targeted HBV (HBx and HBcAg), implying that their gammopathy was HBV-driven, received AVT and the gammopathy did not progress. AVT efficacy was then investigated in a large cohort of HBV-infected MM patients (n=1367) who received or did not receive anti-HBV treatments and compared to a cohort of HCV-infected MM patients (n=1220). AVT significantly improved patient probability of overall survival (P=0.016 for the HBV-positive cohort, P=0.005 for the HCV-positive cohort). Altogether, MGUS and MM disease can be HBV- or HCV-driven in infected patients, and the study demonstrates the importance of AVT in such patients.<\/jats:p>","DOI":"10.3324\/haematol.2023.283096","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T09:53:24Z","timestamp":1684403604000},"page":"272-282","source":"Crossref","is-referenced-by-count":5,"title":["Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses"],"prefix":"10.3324","volume":"109","author":[{"given":"Alba","family":"Rodr\u00edguez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mennesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Hernandez-Ibarburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luz","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorine","family":"Bouchereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Allain-Maillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Piver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Marb\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Bigot-Corbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Hermouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"56553","doi-asserted-by":"crossref","unstructured":"Palumbo A, Anderson KC. Multiple myeloma. N Engl J Med. 2011; 364(11):1046-1060.","DOI":"10.1056\/NEJMra1011442"},{"key":"56554","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-e548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"56555","doi-asserted-by":"crossref","unstructured":"Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016; 128(23):2599-2606.","DOI":"10.1182\/blood-2016-09-692954"},{"key":"56556","doi-asserted-by":"crossref","unstructured":"Kyle RA, Larson DR, Therneau TM. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018; 378(3):241-249.","DOI":"10.1056\/NEJMoa1709974"},{"key":"56557","doi-asserted-by":"crossref","unstructured":"Boyle EM, Davies FE, Leleu X, Morgan GJ. Understanding the multiple biological aspects leading to myeloma. Haematologica. 2014; 99(4):605-612.","DOI":"10.3324\/haematol.2013.097907"},{"key":"56558","doi-asserted-by":"crossref","unstructured":"Guillerey C, Nakamura K, Vuckovic S, Hill GR, Smyth MJ. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci. 2016; 73(8):1569-1589.","DOI":"10.1007\/s00018-016-2135-z"},{"key":"56559","doi-asserted-by":"crossref","unstructured":"Morrison VA. Infections in patients with leukemia and lymphoma. 2014;319-349.","DOI":"10.1007\/978-3-319-04220-6_11"},{"key":"56560","doi-asserted-by":"crossref","unstructured":"Hoogeboom R, van Kessel KPM, Hochstenbach F. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med. 2013; 210(1):59-70.","DOI":"10.1084\/jem.20121801"},{"key":"56561","doi-asserted-by":"crossref","unstructured":"Seifert M, Scholtysik R, K\u00fcppers R. Origin and pathogenesis of B cell lymphomas. 2019;1-33.","DOI":"10.1007\/978-1-4939-9151-8_1"},{"key":"56562","doi-asserted-by":"crossref","unstructured":"Stevenson FK, Forconi F, Kipps TJ. Exploring the pathways to chronic lymphocytic leukemia. Blood. 2021; 138(10):827-835.","DOI":"10.1182\/blood.2020010029"},{"key":"56563","doi-asserted-by":"crossref","unstructured":"Stevens WBC, Netea MG, Kater AP, van der Velden WJFM. Trained immunity: consequences for lymphoid malignancies. Haematologica. 2016; 101(12):1460-1468.","DOI":"10.3324\/haematol.2016.149252"},{"key":"56564","doi-asserted-by":"crossref","unstructured":"Hermouet S, Corre I, Gassin M, Bigot-Corbel E, Sutton CA, Casey JW. Hepatitis C virus, human herpesvirus 8, and the development of plasma-cell leukemia. N Engl J Med. 2003; 348(2):178-179.","DOI":"10.1056\/NEJM200301093480219"},{"key":"56565","doi-asserted-by":"crossref","unstructured":"Bigot-Corbel E, Gassin M, Corre I, Le Carrer D, Delaroche O, Hermouet S. Hepatitis C virus (HCV) infection, monoclonal immunoglobulin specific for HCV core protein, and plasma-cell malignancy. Blood. 2008; 112(10):4357-4358.","DOI":"10.1182\/blood-2008-07-167569"},{"key":"56566","doi-asserted-by":"crossref","unstructured":"McShane CM, Murray LJ, Engels EA, Landgren O, Anderson LA. Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study: infections and multiple myeloma. Int J Cancer. 2014; 134(7):1734-1740.","DOI":"10.1002\/ijc.28479"},{"key":"56567","doi-asserted-by":"crossref","unstructured":"Li Y, Li Y, Zhang L, Li W. Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies. J Viral Hepat. 2017; 24(12):1151-1159.","DOI":"10.1111\/jvh.12742"},{"key":"56568","doi-asserted-by":"crossref","unstructured":"Yan J, Wang J, Zhang W, Chen M, Chen J, Liu W. Solitary plasmacytoma associated with Epstein-Barr virus: a clinicopathologic, cytogenetic study and literature review. Ann Diagn Pathol. 2017; 27:1-6.","DOI":"10.1016\/j.anndiagpath.2016.09.002"},{"key":"56569","doi-asserted-by":"crossref","unstructured":"Bosseboeuf A, Feron D, Tallet A. Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens. JCI Insight. 2017; 2(19):e95367.","DOI":"10.1172\/jci.insight.95367"},{"key":"56570","doi-asserted-by":"crossref","unstructured":"Bosseboeuf A, Seillier C, Mennesson N. Analysis of the targets and glycosylation of monoclonal IgAs from MGUS and myeloma patients. Front Immunol. 2020; 11:854.","DOI":"10.3389\/fimmu.2020.00854"},{"key":"56571","doi-asserted-by":"crossref","unstructured":"Bosseboeuf A, Mennesson N, Allain-Maillet S. Characteristics of MGUS and multiple myeloma according to the target of monoclonal immunoglobulins, glucosylsphingosine, or Epstein-Barr virus EBNA-1. Cancers (Basel). 2020; 12(5):1254.","DOI":"10.3390\/cancers12051254"},{"key":"56572","doi-asserted-by":"crossref","unstructured":"Harb J, Mennesson N, Lepetit C. Comparison of monoclonal gammopathies linked to poliovirus or coxsackievirus vs. other infectious pathogens. Cells. 2021; 10(2):438.","DOI":"10.3390\/cells10020438"},{"key":"56573","doi-asserted-by":"crossref","unstructured":"Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. Clonal immunoglobulin against lysolipids in the origin of myeloma. N Engl J Med. 2016; 374(6):555-561.","DOI":"10.1056\/NEJMoa1508808"},{"key":"56574","doi-asserted-by":"crossref","unstructured":"Nair S, Sng J, Boddupalli CS. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight. 2018; 3(8):e98259.","DOI":"10.1172\/jci.insight.98259"},{"key":"56575","doi-asserted-by":"crossref","unstructured":"Nair S, Bar N, Xu ML, Dhodapkar M, Mistry PK. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Mol Genet Metab. 2020; 129(4):286-291.","DOI":"10.1016\/j.ymgme.2020.01.009"},{"key":"56576","doi-asserted-by":"crossref","unstructured":"Panfilio S, D\u2019Urso P, Annechini G. Regression of a case of multiple myeloma with antiviral treatment in a patient with chronic HCV infection. Leuk Res Rep. 2013; 2(1):39-40.","DOI":"10.1016\/j.lrr.2013.01.002"},{"key":"56577","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Garc\u00eda A, Linares M, Morales ML. Efficacy of antiviral treatment in hepatitis C virus (HCV)-driven monoclonal gammopathies including myeloma. Front Immunol. 2022; 12:797209.","DOI":"10.3389\/fimmu.2021.797209"},{"key":"56578","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"56579","doi-asserted-by":"crossref","unstructured":"Bosseboeuf A, Allain-Maillet S, Mennesson N. Pro-inflammatory state in monoclonal gammopathy of undetermined significance and in multiple myeloma is characterized by low sialylation of pathogen-specific and other monoclonal immunoglobulins. Front Immunol. 2017; 8:1347.","DOI":"10.3389\/fimmu.2017.01347"},{"key":"56580","doi-asserted-by":"crossref","unstructured":"Feron D, Charlier C, Gourain V. Multiplexed infectious protein microarray immunoassay suitable for the study of the specificity of monoclonal immunoglobulins. Anal Biochem. 2013; 433(2):202-209.","DOI":"10.1016\/j.ab.2012.10.012"},{"key":"56581","doi-asserted-by":"crossref","unstructured":"Linares M, Hermouet S. Editorial: the role of microorganisms in multiple myeloma. Front Immunol. 2022; 13:960829.","DOI":"10.3389\/fimmu.2022.960829"},{"key":"56582","doi-asserted-by":"crossref","unstructured":"Im YR, Jagdish R, Leith D. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(10):932-942.","DOI":"10.1016\/S2468-1253(22)00201-1"},{"key":"56583","doi-asserted-by":"crossref","unstructured":"Zhao F, Xie X, Tan X. The functions of hepatitis B virus encoding proteins: viral persistence and liver pathogenesis. Front Immunol. 2021; 12:691766.","DOI":"10.3389\/fimmu.2021.691766"},{"key":"56584","doi-asserted-by":"crossref","unstructured":"Feitelson MA, Bonamassa B, Arzumanyan A. The roles of hepatitis B virus-encoded X protein in virus replication and the pathogenesis of chronic liver disease. Expert Opin Ther Targets. 2014; 18(3):293-306.","DOI":"10.1517\/14728222.2014.867947"},{"key":"56585","doi-asserted-by":"crossref","unstructured":"Slagle BL, Bouchard MJ. Role of HBx in hepatitis B virus persistence and its therapeutic implications. Curr Opin Virol. 2018; 30:32-38.","DOI":"10.1016\/j.coviro.2018.01.007"},{"key":"56586","doi-asserted-by":"crossref","unstructured":"You H, Qin S, Zhang F. Regulation of pattern-recognition receptor signaling by HBX during hepatitis B virus infection. Front Immunol. 2022; 13:829923.","DOI":"10.3389\/fimmu.2022.829923"},{"key":"56587","doi-asserted-by":"crossref","unstructured":"Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol. 1997; 71(12):9392-9399.","DOI":"10.1128\/jvi.71.12.9392-9399.1997"},{"key":"56588","doi-asserted-by":"crossref","unstructured":"Ogawa E, Nakamuta M, Koyanagi T. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study. Hepatol Int. 2022; 16(2):282-293.","DOI":"10.1007\/s12072-021-10295-3"},{"key":"56589","doi-asserted-by":"crossref","unstructured":"Tu T, Zehnder B, Wettengel JM. Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells. JHEP Rep. 2022; 4(9):100514.","DOI":"10.1016\/j.jhepr.2022.100514"},{"key":"56590","doi-asserted-by":"crossref","unstructured":"Zhang H, Wu L-Y, Zhang S. Anti-hepatitis B virus X protein in sera is one of the markers of development of liver cirrhosis and liver cancer mediated by HBV. J Biomed Biotechnol. 2009; 2009:289068.","DOI":"10.1155\/2009\/289068"},{"key":"56591","doi-asserted-by":"crossref","unstructured":"Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?. J Hepatol. 2017; 67(6):1281-1297.","DOI":"10.1016\/j.jhep.2017.07.011"},{"key":"56592","doi-asserted-by":"crossref","unstructured":"Levrero M, Stemler M, Pasquinelli C. Significance of anti-HBx antibodies in hepatitis B virus infection. Hepatology. 1991; 13(1):143-149.","DOI":"10.1016\/0270-9139(91)90227-M"},{"key":"56593","doi-asserted-by":"crossref","unstructured":"Hoare J, Henkler F, Dowling JJ. Subcellular localisation of the X protein in HBV infected hepatocytes. J Med Virol. 2001; 64(4):419-426.","DOI":"10.1002\/jmv.1067"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283096\/75623","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283096\/76453","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11089\/75623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:05Z","timestamp":1794045845000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283096","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,18]]}}}